tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

IceCure Medical Showcases ProSense® Success at CIRSE 2025

Story Highlights
IceCure Medical Showcases ProSense® Success at CIRSE 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Icecure Medical ( (ICCM) ) has provided an update.

On September 22, 2025, IceCure Medical announced its successful participation at the CIRSE 2025 Annual Meeting, where their ProSense® cryoablation system was prominently featured. The event highlighted positive clinical results from four independent studies, demonstrating ProSense®’s efficacy in treating breast cancer and endometriosis. The presentations underscored the growing interest among interventional radiologists in using cryoablation as a viable alternative to traditional surgical methods, potentially enhancing IceCure’s industry positioning and offering significant implications for stakeholders in terms of expanding treatment options.

The most recent analyst rating on (ICCM) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s overall stock score is driven by significant financial challenges, including declining revenues and ongoing losses, which weigh heavily on the score. Despite these issues, the company’s strong regulatory progress and clinical achievements, particularly with ProSense, provide a positive outlook. Technical indicators suggest some stability, but valuation concerns persist due to the negative P/E ratio and lack of dividend yield.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical, listed on Nasdaq as ICCM, is a developer and marketer of advanced cryoablation therapy systems using liquid nitrogen to destroy tumors. Their primary focus areas include breast, kidney, bone, and lung cancer. The company’s flagship product, ProSense®, offers a minimally invasive alternative to surgical tumor removal and is marketed globally.

Average Trading Volume: 1,767,756

Technical Sentiment Signal: Hold

Current Market Cap: $72.13M

For detailed information about ICCM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1